Ascoril Expectorant

Ascoril expectorant: a drug for the treatment of bronchospastic conditions

Ascoril expectorant is a combination drug produced by the Indian pharmaceutical company Glenmark Pharmaceuticals Ltd. It contains several active ingredients including salbutamol, bromhexine hydrochloride, guaifenesin and menthol. The drug is presented in the form of syrup and is intended for the treatment of bronchospastic conditions.

Salbutamol is a bronchodilator that dilates the bronchi and improves air flow in the lungs. Bromhexine hydrochloride is a mucolytic agent that improves sputum discharge. Guaifenesin is also a mucolytic agent, and menthol has an expectorant effect and reduces irritation of the mucous membrane of the respiratory tract.

Ascoril expectorant is indicated for the treatment of bronchial asthma, emphysema, atelectasis, acute and chronic bronchitis, bronchiectasis, pulmonary tuberculosis, whooping cough, pneumonia and other bronchospastic conditions.

The drug should be prescribed with caution to patients with hyperthyroidism, diabetes mellitus, severe cardiovascular disease, hypertension and peptic ulcers.

Side effects sometimes observed with the use of Ascoril Expectorant may include musculoskeletal tremors, rapid heart rate, muscle cramps, mild tachycardia, headache and peripheral vasodilation.

There is no data on the interaction of the drug with other drugs, or on an overdose of Ascoril expectorant.

In general, Ascoril expectorant is an effective and safe drug for the treatment of bronchospastic conditions. However, like any other drug, it should be used only as prescribed by a doctor and in accordance with the instructions for use.